Breakthroughs happen when the right elements combine—both in science and in business. As experts in organic chemistry, cardiovascular surgery, and business development, we bring the scientific precision and vision needed to push healthcare forward.

But we also know that true magic happens with the right chemistry between a founding team and investors. If you’re looking for a partner where expertise meets synergy, call us and let’s create something transformative together.

The MediGuide advantage goes beyond IP.

We’re deep tech entrepreneurs from Ljubljana, Slovenia (EU), with interdisciplinary expertise. Our team holds 8 approved patents and has successfully launched 2 startups in the past, bringing advanced technologies to market.

Building on a strong foundation in academic research and value-based healthcare, we focus on solving critical challenges in healthcare. We are committed to enhancing surgical outcomes and improving patient care.

Rapid market growth with 16.8% CAGR.

Every year surgical complications and errors generate €450B in excess costs to the healthcare system in EU & US combined. These costs are avoidable, when surgical teams arrive in the OR ready for each case. Like in the theatere - every premiere needs a final rehearsal. So should surgery.

The global surgical simulation market is projected to grow rapidly, reaching $7.2 billion by 2030 at a compound annual growth rate (CAGR) of 16.8%. This strong trajectory underscores the increasing demand for cutting-edge surgical training and planning tools, as healthcare systems worldwide prioritize innovation, precision, and efficiency.

This is where MediGuide creates a unique business opportunity by addressing a critical gap that has hindered the widespread adoption of 3D printing in healthcare. The potential to save lives, improve quality of life, and enhance patient engagement further underscores our focus, driving our commitment to transformative patient care solutions.

We are advancing to TRL 6-7 in 2026.

Our active collaborations will enable us to advance our solutions to TRL 6-7, focusing on refinement through joint pilot and research programs with leading hospitals and medical universities in Slovenia and EU. We expect to reach this milestone by the end of 2026. 

Our PoC and validation efforts have already demonstrated significant improvements in surgical training and enhanced patient understanding, reinforcing the clinical and educational impact of our solutions. The next key steps include protection of IP and securing a strategic licensing agreement.

Join us in shaping the future of healthcare.